ClinicalTrials.gg
CompletedNCT07587008Updated Aug 14, 2026

Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy Volunteers

A Phase 1 interventional study of Emraclidine in Healthy Volunteers, sponsored by AbbVie. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The objective of this study is to evaluate the pharmacokinetics (PK) and relative bioavailability of emraclidine following single oral administration of different immediate-release (IR) tablet formulations in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers
  • Emraclidine
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • of 18.5 to 32.0 kg/m2, inclusive.
  • Total body weight >= 50 kg.

Exclusion criteria

Exclusion Criteria:

  • History of suicidal ideation within one year prior to study treatment administration and/or history of suicidal behavior or non-suicidal self-injury within two years prior to study treatment administration as evidenced by any "yes" answer to questions on the Columbia-Suicide Severity Rating Scale (C-SSRS) at the screening visit or upon initial confinement.
  • Vital sign measurements, at Screening and Check-in:

    • Systolic blood pressure >= 140 mmHg or \< 100 mmHg
    • Diastolic blood pressure >= 90 mmHg or \< 60 mmHg
    • Heart rate > 100 bpm or \< 50 bpm
    • Orthostatic hypotension, defined as a decrease of >= 20 mmHg in systolic blood pressure upon standing compared with the supine/sitting blood pressure measurement.
  • Female participants of
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Participants will receive Emraclidine in 3 different formulations in Sequence 1.

    Drug: Emraclidine

  • Experimental
    Sequence 2

    Participants will receive Emraclidine in 3 different formulations in Sequence 2.

    Drug: Emraclidine

  • Experimental
    Sequence 3

    Participants will receive Emraclidine in 3 different formulations in Sequence 3.

    Drug: Emraclidine

  • Experimental
    Sequence 4

    Participants will receive Emraclidine in 3 different formulations in Sequence 4.

    Drug: Emraclidine

  • Experimental
    Sequence 5

    Participants will receive Emraclidine in 3 different formulations in Sequence 5.

    Drug: Emraclidine

  • Experimental
    Sequence 6

    Participants will receive Emraclidine in 3 different formulations in Sequence 6.

    Drug: Emraclidine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

    Time frame: Up to approximately 44 days

  2. Maximum Observed Plasma Concentration (Cmax) of Emraclidine

    Cmax of Emraclidine.

    Time frame: Up to approximately 14 days

  3. Time to Cmax (Tmax) of Emraclidine

    Tmax of Emraclidine.

    Time frame: Up to approximately 14 days

  4. Area Under the Concentration-Time Curve from Time 0 to Time t (AUC) of Emraclidine

    AUC of Emraclidine.

    Time frame: Up to approximately 14 days

07

Study locations

1 site
  • Acpru /Id# 283349
    Grayslake, Illinois 60030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2026 to primary completion in Jul 2026, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
May 14, 2026
StartActual
May 12, 2026
Primary completionActual
Jul 17, 2026
CompletionActual
Jul 17, 2026
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07587008
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 14, 2026
Start date
May 12, 2026
Primary completion
Jul 17, 2026
Completion
Jul 17, 2026
Last update
Aug 14, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emraclidine

Start the discussion